Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Combination Therapies for Gonorrhea Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female from 15 - 60 years old.~* Is either:~  1. Untreated male or female with urethral or cervical gonorrhea as determined by a screening laboratory test \[either Nucleic Acid Amplification Test (NAAT) or culture\] for Neisseria gonorrhoeae at a prior visit.~ 2. Urethral or cervical gram stain demonstrating gram negative intracellular diplococci and leukocytes.~ 3. Untreated male or female who is a sexual contact (anal, oral, or vaginal) of an individual with gonorrhea in the past 60 days.~* Willing to abstain from anal, oral, or vaginal sexual intercourse or use condoms until follow up is completed.~* Willing to follow up from 10 to 17 days following enrollment.~* Willing to provide written consent.~* Able to swallow pills.~Exclusion Criteria:~* Known renal insufficiency from clinical history~* Known hepatic insufficiency from clinical history~* Known QT interval prolongation from clinical history~* Known neuromuscular disorder from clinical history (i.e., myasthenia gravis or Parkinson's disease)~* Known rheumatoid arthritis or tendon disorders from clinical history~* Known kidney, heart, or lung transplants from clinical history~* Pregnant women (determined by positive urine pregnancy test)~* Breastfeeding women~* Known allergy or adverse reaction to macrolides, aminoglycosides, or quinolones~* Concomitant infection (besides chlamydia or bacterial vaginosis) which requires systemic antibiotics~* Has received systemic or intravaginal antibiotics within 30 days of study enrollment~* Currently taking corticosteroid drugs or other immunosuppressive therapy~* Currently taking cardiac antiarrhythmia drugs~* Self report of or clinical diagnosis of abdominal pain, pelvic inflammatory disease (PID), testicular pain, epididymitis, or disseminated gonococcal infection~* Self report of or clinical diagnosis of current genital ulcer (GU)~* In the judgment of the interviewer, has a medical condition or other factor that might affect their ability to follow the protocol~* Previous enrollment in this study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Regimen B: gemifloxacin plus azithromycin (Type: EXPERIMENTAL): Gemifloxacin 320 mg by mouth one time plus azithromycin 2 gm by mouth one time.
- Regimen A: gentamicin plus azithromycin (Type: EXPERIMENTAL): Gentamicin 240 mg intramuscular (IM) one time for patients greater than 45 kg or 5 mg/kg IM one time for patients less than or equal to 45 kg plus azithromycin 2 gm by mouth one time.

Based on this trial design, predict the completion outcome and termination type (if applicable).